• Gan To Kagaku Ryoho · Jan 2013

    [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].

    • Emi Noguchi and Chikako Shimizu.
    • Division of Breast and Medical Oncology, National Cancer Center Hospital, Japan.
    • Gan To Kagaku Ryoho. 2013 Jan 1;40(1):10-4.

    AbstractHER2-targeted therapy for HER2-positive breast cancer is one of the success stories in medical oncology. Trastuzumab, a humanized monoclonal antibody, was the first approved HER2-targeted agent. Subsequent developments include agents with different mechanisms, such as lapatinib, a tyrosine kinase inhibitor. We describe here the results of late-phase clinical trials of two newly-available anti-HER2 agents, T-DM1 and pertuzumab.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.